首页> 外文期刊>American Journal of Ophthalmology: The International Journal of Ophthalmology >Eight-year follow-up of posterior chamber phakic intraocular lens implantation for moderate to high myopia
【24h】

Eight-year follow-up of posterior chamber phakic intraocular lens implantation for moderate to high myopia

机译:中度至高度近视眼后房型人工晶状体植入术后八年随访

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose To assess the long-term clinical outcomes of Implantable Collamer Lens (Visian ICL; STAAR Surgical) implantation for moderate to high myopia. Design Retrospective observational case series. Methods This study evaluated 41 eyes of 41 patients with myopic refractive errors of -4.00 to -15.25 diopters (D) who underwent ICL implantation and routine postoperative examinations. Before surgery, and 1 and 6 months and 1, 4 and 8 years after surgery, we assessed the safety, efficacy, predictability, stability, and adverse events of the surgery. Results The safety and efficacy indices were 1.13 ± 0.27 and 0.83 ± 0.36. At 8 years, 68.3% and 85.4% of the eyes were within 0.5 and 1.0 D, respectively, of the targeted correction. Manifest refraction changes of -0.32 ± 0.73 D occurred between 1 month and 8 years. The mean endothelial cell loss from preoperative levels was 6.2% at 8 years. Two eyes (4.9%) developed clinically significant symptomatic cataract during the follow-up period. Simultaneous lens extraction and phacoemulsification with IOL implantation was successfully performed in these 2 eyes. Conclusions According to our experience, ICL implantation was overall good in measures of safety, efficacy, predictability, and stability for the correction of moderate to high myopia during the 8-year observation period, suggesting its long-term viability as a surgical option for the treatment of such eyes.
机译:目的评估中度至高度近视眼植入式可植入矫正镜(Visian ICL; STAAR Surgical)的长期临床效果。设计回顾性观察病例系列。方法该研究评估了41例接受ICL植入和常规术后检查的近视屈光度为-4.00至-15.25屈光度(D)的患者的41只眼。手术前,手术后1和6个月以及手术后1、4和8年,我们评估了手术的安全性,有效性,可预测性,稳定性和不良事件。结果安全性和有效性指数分别为1.13±0.27和0.83±0.36。在8年时,分别有68.3%和85.4%的眼睛在目标矫正范围之内,分别在0.5和1.0 D之内。在1个月至8年之间,明显的屈光度变化为-0.32±0.73D。术前平均内皮细胞流失率在8年时为6.2%。在随访期间,两只眼睛(4.9%)出现了临床上明显的症状性白内障。在这两只眼睛中成功地同时进行了晶状体摘除和人工晶状体植入术的超声乳化。结论根据我们的经验,在8年的观察期内,ICL植入在安全性,有效性,可预测性和稳定性方面总体上良好,可矫正中至高度近视,这表明ICL植入可作为长期手术的可行性。这种眼睛的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号